93 related articles for article (PubMed ID: 7528003)
1. T cell epitopes in human papilloma virus proteins.
Sadovnikova E; Stauss HJ
Behring Inst Mitt; 1994 Jul; (94):87-93. PubMed ID: 7528003
[TBL] [Abstract][Full Text] [Related]
2. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
Ressing ME; Sette A; Brandt RM; Ruppert J; Wentworth PA; Hartman M; Oseroff C; Grey HM; Melief CJ; Kast WM
J Immunol; 1995 Jun; 154(11):5934-43. PubMed ID: 7538538
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus antibody responses among patients with incident cervical carcinoma.
Wang Z; Konya J; Avall-Lundkvist E; Sapp M; Dillner J; Dillner L
J Med Virol; 1997 Aug; 52(4):436-40. PubMed ID: 9260694
[TBL] [Abstract][Full Text] [Related]
4. Presence of antibody reactive with synthetic peptide derived from L2 open reading frame of human papillomavirus types 6b and 11 in human sera.
Suchánková A; Ritter O; Hirsch I; Krchnák V; Kalos Z; Hamsíková E; Brichácek B; Vonka V
Acta Virol; 1990 Sep; 34(5):433-42. PubMed ID: 1705748
[TBL] [Abstract][Full Text] [Related]
5. The role of the immune system in anogenital human papillomavirus.
Frazer IH
Australas J Dermatol; 1998 Nov; 39 Suppl 1():S5-7. PubMed ID: 9842093
[TBL] [Abstract][Full Text] [Related]
6. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
Welters MJ; de Jong A; van den Eeden SJ; van der Hulst JM; Kwappenberg KM; Hassane S; Franken KL; Drijfhout JW; Fleuren GJ; Kenter G; Melief CJ; Offringa R; van der Burg SH
Cancer Res; 2003 Feb; 63(3):636-41. PubMed ID: 12566307
[TBL] [Abstract][Full Text] [Related]
7. The immunology of genital human papilloma virus infection.
Stanley M
Eur J Dermatol; 1998; 8(7 Suppl):8-12; discussion 20-2. PubMed ID: 10387957
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of human papilloma virus-DNA in condyloma acuminatum, cervical cancer and the female genital tract].
Cui M; Zheng P; Huang B
Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):163-5. PubMed ID: 8758791
[TBL] [Abstract][Full Text] [Related]
9. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.
Youde SJ; Dunbar PR; Evans EM; Fiander AN; Borysiewicz LK; Cerundolo V; Man S
Cancer Res; 2000 Jan; 60(2):365-71. PubMed ID: 10667589
[TBL] [Abstract][Full Text] [Related]
10. Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease.
Frazer IH; Leippe DM; Dunn LA; Liem A; Tindle RW; Fernando GJ; Phelps WC; Lambert PF
Cancer Res; 1995 Jun; 55(12):2635-9. PubMed ID: 7540107
[TBL] [Abstract][Full Text] [Related]
11. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
Peng S; Frazer IH; Fernando GJ; Zhou J
Virology; 1998 Jan; 240(1):147-57. PubMed ID: 9448699
[TBL] [Abstract][Full Text] [Related]
12. [Immunohistochemical study of condyloma and and carcinoembryonic antigens in the uterine cervix in human papilloma virus infection and neoplasia].
Alcántara-Vázquez A; Rodríguez-Martínez HA; Gómez-Ramírez AM; Cruz-Ortiz H; Orozco-Estéves H
Rev Invest Clin; 1985; 37(4):291-6. PubMed ID: 3006200
[No Abstract] [Full Text] [Related]
13. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells.
Hu G; Liu W; Hanania EG; Fu S; Wang T; Deisseroth AB
Cancer Gene Ther; 1995 Mar; 2(1):19-32. PubMed ID: 7621252
[TBL] [Abstract][Full Text] [Related]
14. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
15. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and natural history of genital human papillomavirus infection.
Weaver BA
J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S2-8. PubMed ID: 16729554
[TBL] [Abstract][Full Text] [Related]
17. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
[TBL] [Abstract][Full Text] [Related]
18. [Recombinant therapeutic vaccines against cancer of the uterine cervix].
Berumen J; Villegas N
Salud Publica Mex; 1997; 39(4):288-97. PubMed ID: 9381250
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus vaccine development.
Fife KH
Australas J Dermatol; 1998 Nov; 39 Suppl 1():S8-10. PubMed ID: 9842094
[TBL] [Abstract][Full Text] [Related]
20. CD8+CD45RA+CD27-CD28-T-cell subset in PBL of cervical cancer patients representing CD8+T-cells being able to recognize cervical cancer associated antigens provided by HPV 16 E7.
Pilch H; Hoehn H; Schmidt M; Steiner E; Tanner B; Seufert R; Maeurer M
Zentralbl Gynakol; 2002; 124(8-9):406-12. PubMed ID: 12655469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
